Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Double positive CD4+CD8+ T cells are part of the adaptive immune response against Candida albicans.

Misme-Aucouturier B, Touahri A, Albassier M, Jotereau F, Le Pape P, Alvarez-Rueda N.

Hum Immunol. 2019 Sep 24. pii: S0198-8859(19)30997-8. doi: 10.1016/j.humimm.2019.09.008. [Epub ahead of print]

PMID:
31561914
2.

Faecalibacterium prausnitzii Skews Human DC to Prime IL10-Producing T Cells Through TLR2/6/JNK Signaling and IL-10, IL-27, CD39, and IDO-1 Induction.

Alameddine J, Godefroy E, Papargyris L, Sarrabayrouse G, Tabiasco J, Bridonneau C, Yazdanbakhsh K, Sokol H, Altare F, Jotereau F.

Front Immunol. 2019 Feb 6;10:143. doi: 10.3389/fimmu.2019.00143. eCollection 2019.

3.

Expression of CCR6 and CXCR6 by Gut-Derived CD4+/CD8α+ T-Regulatory Cells, Which Are Decreased in Blood Samples From Patients With Inflammatory Bowel Diseases.

Godefroy E, Alameddine J, Montassier E, Mathé J, Desfrançois-Noël J, Marec N, Bossard C, Jarry A, Bridonneau C, Le Roy A, Sarrabayrouse G, Kerdreux E, Bourreille A, Sokol H, Jotereau F, Altare F.

Gastroenterology. 2018 Oct;155(4):1205-1217. doi: 10.1053/j.gastro.2018.06.078. Epub 2018 Jul 5.

PMID:
29981781
4.

Microbiota-Specific CD4CD8αα Tregs: Role in Intestinal Immune Homeostasis and Implications for IBD.

Sarrabayrouse G, Alameddine J, Altare F, Jotereau F.

Front Immunol. 2015 Oct 8;6:522. doi: 10.3389/fimmu.2015.00522. eCollection 2015. Review.

5.

Activation of toll-like receptor-2 by endogenous matrix metalloproteinase-2 modulates dendritic-cell-mediated inflammatory responses.

Godefroy E, Gallois A, Idoyaga J, Merad M, Tung N, Monu N, Saenger Y, Fu Y, Ravindran R, Pulendran B, Jotereau F, Trombetta S, Bhardwaj N.

Cell Rep. 2014 Dec 11;9(5):1856-1870. doi: 10.1016/j.celrep.2014.10.067. Epub 2014 Nov 26.

6.

CD4CD8αα lymphocytes, a novel human regulatory T cell subset induced by colonic bacteria and deficient in patients with inflammatory bowel disease.

Sarrabayrouse G, Bossard C, Chauvin JM, Jarry A, Meurette G, Quévrain E, Bridonneau C, Preisser L, Asehnoune K, Labarrière N, Altare F, Sokol H, Jotereau F.

PLoS Biol. 2014 Apr 8;12(4):e1001833. doi: 10.1371/journal.pbio.1001833. eCollection 2014 Apr.

7.

Cross-presentation of synthetic long peptides by human dendritic cells: a process dependent on ERAD component p97/VCP but Not sec61 and/or Derlin-1.

Ménager J, Ebstein F, Oger R, Hulin P, Nedellec S, Duverger E, Lehmann A, Kloetzel PM, Jotereau F, Guilloux Y.

PLoS One. 2014 Feb 27;9(2):e89897. doi: 10.1371/journal.pone.0089897. eCollection 2014.

8.

A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming.

Michaux A, Larrieu P, Stroobant V, Fonteneau JF, Jotereau F, Van den Eynde BJ, Moreau-Aubry A, Vigneron N.

J Immunol. 2014 Feb 15;192(4):1962-71. doi: 10.4049/jimmunol.1302032. Epub 2014 Jan 22.

9.

Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility?

Jotereau F, Gervois N, Labarrière N.

Target Oncol. 2012 Mar;7(1):3-14. doi: 10.1007/s11523-012-0207-z. Epub 2012 Feb 15. Review.

PMID:
22350487
10.

HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells.

Chauvin JM, Larrieu P, Sarrabayrouse G, Prévost-Blondel A, Lengagne R, Desfrançois J, Labarrière N, Jotereau F.

J Immunol. 2012 Mar 1;188(5):2102-10. doi: 10.4049/jimmunol.1101807. Epub 2012 Jan 30.

11.

HLA-E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression.

Bossard C, Bézieau S, Matysiak-Budnik T, Volteau C, Laboisse CL, Jotereau F, Mosnier JF.

Int J Cancer. 2012 Aug 15;131(4):855-63. doi: 10.1002/ijc.26453. Epub 2012 Apr 5.

12.

Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway.

Godefroy E, Manches O, Dréno B, Hochman T, Rolnitzky L, Labarrière N, Guilloux Y, Goldberg J, Jotereau F, Bhardwaj N.

Cancer Cell. 2011 Mar 8;19(3):333-46. doi: 10.1016/j.ccr.2011.01.037.

13.

Tumor-reactive CD4+ CD8αβ+ CD103+ αβT cells: a prevalent tumor-reactive T-cell subset in metastatic colorectal cancers.

Sarrabayrouse G, Corvaisier M, Ouisse LH, Bossard C, Le Mével B, Potiron L, Meurette G, Gervois N, Jotereau F.

Int J Cancer. 2011 Jun 15;128(12):2923-32. doi: 10.1002/ijc.25640. Epub 2010 Dec 1.

14.

Crystal structures of HLA-A*0201 complexed with Melan-A/MART-1(26(27L)-35) peptidomimetics reveal conformational heterogeneity and highlight degeneracy of T cell recognition.

Douat-Casassus C, Borbulevych O, Tarbe M, Gervois N, Jotereau F, Baker BM, Quideau S.

J Med Chem. 2010 Oct 14;53(19):7061-6. doi: 10.1021/jm100683p.

15.

Folding of matrix metalloproteinase-2 prevents endogenous generation of MHC class-I restricted epitope.

Renaud V, Godefroy E, Larrieu P, Fleury F, Jotereau F, Guilloux Y.

PLoS One. 2010 Jul 30;5(7):e11894. doi: 10.1371/journal.pone.0011894.

16.

Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy.

Godet Y, Desfrançois J, Vignard V, Schadendorf D, Khammari A, Dreno B, Jotereau F, Labarrière N.

Eur J Immunol. 2010 Jun;40(6):1786-94. doi: 10.1002/eji.200940132.

17.

Double positive CD4CD8 alphabeta T cells: a new tumor-reactive population in human melanomas.

Desfrançois J, Moreau-Aubry A, Vignard V, Godet Y, Khammari A, Dréno B, Jotereau F, Gervois N.

PLoS One. 2010 Jan 5;5(1):e8437. doi: 10.1371/journal.pone.0008437.

18.

An additional ORF on meloe cDNA encodes a new melanoma antigen, MELOE-2, recognized by melanoma-specific T cells in the HLA-A2 context.

Godet Y, Moreau-Aubry A, Mompelat D, Vignard V, Khammari A, Dreno B, Lang F, Jotereau F, Labarriere N.

Cancer Immunol Immunother. 2010 Mar;59(3):431-9. doi: 10.1007/s00262-009-0762-z.

PMID:
19730858
19.

Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones.

Khammari A, Labarrière N, Vignard V, Nguyen JM, Pandolfino MC, Knol AC, Quéreux G, Saiagh S, Brocard A, Jotereau F, Dreno B.

J Invest Dermatol. 2009 Dec;129(12):2835-42. doi: 10.1038/jid.2009.144. Epub 2009 Jun 25.

20.

Increased frequency of nonconventional double positive CD4CD8 alphabeta T cells in human breast pleural effusions.

Desfrançois J, Derré L, Corvaisier M, Le Mével B, Catros V, Jotereau F, Gervois N.

Int J Cancer. 2009 Jul 15;125(2):374-80. doi: 10.1002/ijc.24366.

21.

Long-lasting cross-presentation of tumor antigen in human DC.

Faure F, Mantegazza A, Sadaka C, Sedlik C, Jotereau F, Amigorena S.

Eur J Immunol. 2009 Feb;39(2):380-90. doi: 10.1002/eji.200838669.

22.

MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency.

Godet Y, Moreau-Aubry A, Guilloux Y, Vignard V, Khammari A, Dreno B, Jotereau F, Labarriere N.

J Exp Med. 2008 Oct 27;205(11):2673-82. doi: 10.1084/jem.20081356. Epub 2008 Oct 20.

23.

A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes.

Bouquié R, Bonnin A, Bernardeau K, Khammari A, Dréno B, Jotereau F, Labarrière N, Lang F.

Cancer Immunol Immunother. 2009 Apr;58(4):553-66. doi: 10.1007/s00262-008-0578-2. Epub 2008 Aug 27.

PMID:
18751701
24.

A new tyrosinase epitope recognized in the HLA-B*4002 context by CTL from melanoma patients.

Godet Y, Bonnin A, Guilloux Y, Vignard V, Schadendorf D, Dreno B, Jotereau F, Labarriere N.

Cancer Immunol Immunother. 2009 Feb;58(2):271-80. doi: 10.1007/s00262-008-0551-0. Epub 2008 Jul 9.

PMID:
18612636
25.

Activation of tumor-specific T cells by dendritic cells expressing the NY-ESO-1 antigen after transfection with the cationic lipophosphoramide KLN5.

Le Gallo M, Toutirais O, Montier T, Cabillic F, Bouet F, Delépine P, Lehn P, Jotereau F, Catros V.

J Gene Med. 2008 Jun;10(6):628-36. doi: 10.1002/jgm.1188.

PMID:
18338820
26.

A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes.

Larrieu P, Renaud V, Godet Y, Jotereau F, Fonteneau JF.

Cancer Immunol Immunother. 2008 May;57(5):745-52. Epub 2007 Dec 21.

PMID:
18097665
27.

PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting.

Labarrière N, Gervois N, Bonnin A, Bouquié R, Jotereau F, Lang F.

Cancer Immunol Immunother. 2008 Feb;57(2):185-95. Epub 2007 Jul 24.

PMID:
17646986
28.

Synthesis of glycocluster-tumor antigenic peptide conjugates for dendritic cell targeting.

Srinivas O, Larrieu P, Duverger E, Boccaccio C, Bousser MT, Monsigny M, Fonteneau JF, Jotereau F, Roche AC.

Bioconjug Chem. 2007 Sep-Oct;18(5):1547-54. Epub 2007 Jun 29.

PMID:
17602511
29.

Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma.

Khammari A, Nguyen JM, Pandolfino MC, Quereux G, Brocard A, Bercegeay S, Cassidanius A, Lemarre P, Volteau C, Labarrière N, Jotereau F, Dréno B.

Cancer Immunol Immunother. 2007 Nov;56(11):1853-60. Epub 2007 Jun 5.

PMID:
17549472
30.

Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells.

Douat-Casassus C, Marchand-Geneste N, Diez E, Gervois N, Jotereau F, Quideau S.

J Med Chem. 2007 Apr 5;50(7):1598-609. Epub 2007 Mar 1.

PMID:
17328535
31.

A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes.

Larrieu P, Ouisse LH, Guilloux Y, Jotereau F, Fonteneau JF.

Cancer Immunol Immunother. 2007 Oct;56(10):1565-75. Epub 2007 Feb 23.

PMID:
17318652
32.

Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells.

Derré L, Corvaisier M, Charreau B, Moreau A, Godefroy E, Moreau-Aubry A, Jotereau F, Gervois N.

J Immunol. 2006 Sep 1;177(5):3100-7.

33.

Covalent modification of a melanoma-derived antigenic peptide with a natural quinone methide. Preliminary chemical, molecular modelling and immunological evaluation studies.

Douat-Casassus C, Marchand-Geneste N, Diez E, Aznar C, Picard P, Geoffre S, Huet A, Bourguet-Kondracki ML, Gervois N, Jotereau F, Quideau S.

Mol Biosyst. 2006 May;2(5):240-9. Epub 2006 Mar 22.

PMID:
16880942
34.

Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients.

Benlalam H, Vignard V, Khammari A, Bonnin A, Godet Y, Pandolfino MC, Jotereau F, Dreno B, Labarrière N.

Cancer Immunol Immunother. 2007 Apr;56(4):515-26. Epub 2006 Jul 28.

PMID:
16874485
35.

Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles.

Godefroy E, Scotto L, Souleimanian NE, Ritter G, Old LJ, Jotereau F, Valmori D, Ayyoub M.

Clin Immunol. 2006 Oct;121(1):54-62. Epub 2006 Jun 30.

PMID:
16814609
36.

V gamma 9V delta 2 T cell response to colon carcinoma cells.

Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier JF, Scotet E, Bonneville M, Jotereau F.

J Immunol. 2005 Oct 15;175(8):5481-8.

37.

Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells.

Vignard V, Lemercier B, Lim A, Pandolfino MC, Guilloux Y, Khammari A, Rabu C, Echasserieau K, Lang F, Gougeon ML, Dreno B, Jotereau F, Labarriere N.

J Immunol. 2005 Oct 1;175(7):4797-805.

38.

alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen.

Godefroy E, Moreau-Aubry A, Diez E, Dreno B, Jotereau F, Guilloux Y.

J Exp Med. 2005 Jul 4;202(1):61-72.

39.

Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes.

Faure O, Graff-Dubois S, Bretaudeau L, Derré L, Gross DA, Alves PM, Cornet S, Duffour MT, Chouaib S, Miconnet I, Grégoire M, Jotereau F, Lemonnier FA, Abastado JP, Kosmatopoulos K.

Int J Cancer. 2004 Mar 1;108(6):863-70.

40.

Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.

Benlalam H, Linard B, Guilloux Y, Moreau-Aubry A, Derré L, Diez E, Dreno B, Jotereau F, Labarrière N.

J Immunol. 2003 Dec 1;171(11):6283-9.

41.

[Passive immunotherapy of melanoma].

Jotereau F, Labarriere N, Gervois N, Pandolfino MC, Dreno B.

Bull Cancer. 2003 Jul;90(7):583-6. Review. French.

42.

[Adoptive immunotherapy in solid tumors: new hope].

Jotereau F, Labarrière N, Gervois N, Pandolfino MC, Dreno B.

Med Sci (Paris). 2003 Mar;19(3):268-70. French. No abstract available.

43.

Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen.

Dietrich PY, Le Gal FA, Dutoit V, Pittet MJ, Trautman L, Zippelius A, Cognet I, Widmer V, Walker PR, Michielin O, Guillaume P, Connerotte T, Jotereau F, Coulie PG, Romero P, Cerottini JC, Bonneville M, Valmori D.

J Immunol. 2003 May 15;170(10):5103-9.

44.

Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens.

Trautmann L, Labarrière N, Jotereau F, Karanikas V, Gervois N, Connerotte T, Coulie P, Bonneville M.

Eur J Immunol. 2002 Nov;32(11):3181-90.

45.

Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma.

Dréno B, Nguyen JM, Khammari A, Pandolfino MC, Tessier MH, Bercegeay S, Cassidanius A, Lemarre P, Billaudel S, Labarrière N, Jotereau F.

Cancer Immunol Immunother. 2002 Nov;51(10):539-46. Epub 2002 Sep 19.

PMID:
12384805
46.

Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients.

Labarrière N, Pandolfino MC, Gervois N, Khammari A, Tessier MH, Dréno B, Jotereau F.

Cancer Immunol Immunother. 2002 Nov;51(10):532-8. Epub 2002 Sep 18.

PMID:
12384804
47.

Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen.

Labarrière N, Bretaudeau L, Gervois N, Bodinier M, Bougras G, Diez E, Lang F, Gregoire M, Jotereau F.

Int J Cancer. 2002 Sep 20;101(3):280-6.

48.

Expression of CD94/NKG2-A on human T lymphocytes is induced by IL-12: implications for adoptive immunotherapy.

Derre L, Corvaisier M, Pandolfino MC, Diez E, Jotereau F, Gervois N.

J Immunol. 2002 May 15;168(10):4864-70.

49.

A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion.

Linard B, Bézieau S, Benlalam H, Labarrière N, Guilloux Y, Diez E, Jotereau F.

J Immunol. 2002 May 1;168(9):4802-8.

50.

Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells.

Fonteneau JF, Larsson M, Somersan S, Sanders C, Münz C, Kwok WW, Bhardwaj N, Jotereau F.

J Immunol Methods. 2001 Dec 1;258(1-2):111-26.

PMID:
11684128

Supplemental Content

Loading ...
Support Center